Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant | Aplastic Anemia & MDS International Foundation
Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant

Clinical Trial: NCT03941769

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

 

This phase I trial studies side effects and best dose of recombinant interleukin-7 in promoting immune cell recovery in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, or myeloproliferative disease after a cord blood transplant. Umbilical cord blood is a source of blood-forming cells that can be used for transplant, also known as a graft. However, there is a small number of blood-forming cells available in the transplant, which may delay the "take" of the graft in the recipient. Recombinant interleukin-7 may affect the "take" of the graft and the recovery of certain blood cells related to the immune system (called T-cells, natural killer cells, and B cells) in patients who have had a cord blood transplant.

Status: 
Not yet recruiting
Study Date: 
Wed, 05/08/2019 to Fri, 12/31/2021
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • myelodysplastic syndromes (MDS)
  • myeloproliferative neoplasms (MPN)
Intervention: 
Experimental: Supportive care (recombinant interleukin-7) Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks. Intervention: Biological: Recombinant Interleukin-7